on June 14, 2004
Published online before print June 14, 2004, doi: 10.1161/01.CIR.0000134275.90823.87
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© American Heart Association, Inc.
Basic Science Reports |
Oral D-4F Causes Formation of Pre-ß High-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice
From the David Geffen School of Medicine at the University of California, Los Angeles (M.N., S.T.R., S.H., G.H., V.R.G., A.C.W., J.S.F., A.M.F.), and the Department of Medicine, Atherosclerosis Research Unit, University of Alabama, Birmingham (G.M.A., G.D., D.G.).
Correspondence to Mohamad Navab, PhD, Room 47-123 CHS, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1679. E-mail mnavab{at}mednet.ucla.edu
Received February 10, 2004; de novo received April 13, 2004; revision received April 13, 2004; accepted May 17, 2004.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— These studies were designed to determine the mechanism of action of an oral apolipoprotein (apo) A-I mimetic peptide, D-4F, which previously was shown to dramatically reduce atherosclerosis in mice.
Methods and Results— Twenty minutes after 500 µg of D-4F was given orally to apoE-null mice, small cholesterol-containing particles (CCPs) of 7 to 8 nm with pre-ß mobility and enriched in apoA-I and paraoxonase activity were found in plasma. Before D-4F, both mature HDL and the fast protein liquid chromatography fractions containing the CCPs were proinflammatory. Twenty minutes after oral D-4F, HDL and CCPs became antiinflammatory, and there was an increase in HDL-mediated cholesterol efflux from macrophages in vitro. Oral D-4F also promoted reverse cholesterol transport from intraperitoneally injected cholesterol-loaded macrophages in vivo. In addition, oral D-4F significantly reduced lipoprotein lipid hydroperoxides (LOOH), except for pre-ß HDL fractions, in which LOOH increased.
Conclusions— The mechanism of action of oral D-4F in apoE-null mice involves rapid formation of CCPs, with pre-ß mobility enriched in apoA-I and paraoxonase activity. As a result, lipoprotein LOOH are reduced, HDL becomes antiinflammatory, and HDL-mediated cholesterol efflux and reverse cholesterol transport from macrophages are stimulated.
Key Words: cholesterol • lipoproteins • apolipoproteins
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The apolipoprotein A-I (apoA-I) mimetic peptide 4F contains only 18 amino acids, compared with apoA-I, which contains 243 amino acids. The 4F peptide was designed to contain a class A amphipathic helix with a polar and a nonpolar face that allows it to bind lipids similar to apoA-I.1 4F synthesized from D-amino acids (D-4F) and given orally has been shown to convert HDL from proinflammatory to antiinflammatory and to dramatically reduce atherosclerosis in mice.2 In a mouse model of influenza infection and atherosclerosis, D-4F prevented HDL from becoming proinflammatory and dramatically decreased macrophage traffic into the aortic arch and innominate arteries.3
Ou et al have shown that 4F restores the balance between nitric oxide and superoxide anions in LDL-treated endothelial cells.4 This group has also shown that 4F dramatically improves vasoreactivity in LDL receptor–null mice on a Western diet and in a mouse model of sickle cell disease.5
The present studies indicate that oral D-4F rapidly causes the formation of small cholesterol-containing particles with pre-ß mobility that are enriched in apoA-I and paraoxonase activity, resulting in the conversion of HDL from proinflammatory to antiinflammatory. In addition, HDL-mediated cholesterol efflux and reverse cholesterol transport from macrophages are stimulated.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
1-Palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) (catalogue No. 850459) was from Avanti Polar Lipids. Hydroperoxyoctadecadienoic acid (13[S]-HPODE) was from Biomol. Rabbit polyclonal anti-mouse apoA-I antibody, affinity-purified (catalogue No. K23001R) was from Biodesign International. D-4F (or scrambled D-4F with the same D-amino acids as D-4F but in a sequence that does not promote
helical formation: Ac-DWFAKDYFKKAFVEEFAK-NH2) and D-5F were synthesized as described.1,6 All other materials were from previously cited sources.2
Mice
ApoE-null and wild-type C567/BL6J mice were from The Jackson Laboratory (Bar Harbor, Me) and were maintained on a chow diet (Ralston Purina).
Plasma, Lipoproteins, Cocultures, Monocyte Chemotaxis
Lipoproteins, cocultures, and monocytes were prepared and monocyte chemotaxis assays performed as described previously2,7 using human (after informed consent) or mouse (with Animal Research Committee approval) blood. Plasma was fractionated by gel permeation fast protein liquid chromatography (FPLC) using dual Pharmacia Superose 6 columns in series. Plasma (0.45 mL or less) was eluted with an isocratic buffer containing 154 mmol/L NaCl, 1 mmol/L EDTA, and 0.02% sodium azide, pH 8.2, at a flow rate of 0.5 mL/min, pumped by a nonmetallic Beckman high-performance liquid chromatography (HPLC) pump. Forty-two 1-mL fractions were collected. Lipoproteins isolated in the absence of EDTA contained 20 µmol/L BHT.
Measurement of Plasma Levels of D-4F
Plasma levels of peptides were determined by liquid chromatography multiple reaction monitoring as described.8 Recovery was assessed with 14C-labeled D-4F.
Sample Preparation
Aliquots (20 µL) of plasma were adjusted to d=1.215 with a d=1.33 stock solution (2.9 mol/L KBr containing 2.91 mol/L NaCl and 1 mmol/L EDTA) and brought to a total volume of 175 µL with KBr/NaCl/EDTA (1.5004 mol/L/1.04065 mol/L/0.545 mmol/L, d=1.215) and centrifuged (Beckman-Coulter Airfuge, A100/18 rotor, 148.000g, 4 hours, room temperature). The top 70 µL from 3 tubes was removed, pooled, and diluted 1:3 (vol/vol) with methanol and mixed briefly. Chloroform (210 µL) was added and mixed, yielding a single phase, which was evaporated to dryness in a vacuum centrifuge. The sample was resuspended in 1 mL water and passed over an ODS (C18) cartridge (1 mL x 100 mg, J & W Scientific) that had been equilibrated with 1 cartridge volume of methanol and 3 cartridge volumes of water. The flowthrough was passed over the cartridge a second time, and the cartridge was washed sequentially with water (1 mL) and water/acetonitrile (90/10, vol/vol, 1 mL), and eluted with water/acetonitrile (50/50, vol/vol, 1 mL). The eluate was taken to dryness in a vacuum centrifuge. Some plasma samples were spiked with 10 ng of D-4F for recovery and cochromatography experiments.
HPLC Chromatography
Dried samples were redissolved in 100 µL of water/acetonitrile/formic acid (95/5/0.1, vol/vol/vol) and centrifuged (16 000g, 30 s), and 50 µL of the supernatant was injected onto a reverse-phase HPLC column (C18, BetaBasic-18, Thermo Hypersil-Keystone; 20x2.1 mm, 0.5 µm, 150A pore size) equilibrated with water/acetonitrile/formic acid (95/5/0.1) and eluted (40°C) with an increasing concentration of acetonitrile (min/% acetonitrile: 0/5, 10/50, 12/100 at 150 µL/m, then for a further 5 minutes at 500 µL/m).
Mass Spectrometry
The effluent HPLC column was directed into the Ionspray source of a Perkin-Elmer Sciex API III+ triple-quadripole instrument operated at maximum sensitivity such that there was no resolution between the 13C-satellite ions of the polypropylene glycol calibrant. Data were recorded in the positive-ion tandem mass spectrometry (MS/MS) mode using multiple-reaction monitoring. Recordings were made of the intensity of the transitions m/z 770.7 (triply charged parent) to 159.2 (the most intense signal recorded in the fragment ion spectrum of the m/z 770.7 parent, assigned as [b1+1]+) for D-4F, and m/z 810.1 (triply charged parent) to 159.2 (the most intense signal recorded in the fragment ion spectrum of the m/z 810.1 parent, assigned as [b1+1]+) for the D-5F internal standard when used.
HDL-Mediated Cellular Cholesterol Efflux
Experiments were performed as described by Remaley et al,9 with minor modifications. Human monocytes were obtained as described previously2,7 and converted to macrophages in DMEM high-glucose medium supplemented with 10% FBS. Cells were plated at a density of 5x105 cells per mL in 24-well culture dishes. Twenty-four hours later, the medium was replaced overnight with medium containing 10% lipoprotein deficient serum. The cells were washed, and 1 µCi/mL 3H-labeled cholesterol and 50 µg/mL of acetylated LDL were added and incubated for 48 hours. The cells were washed 3 times and incubated in medium containing 1% BSA to allow cell cholesterol pools to equilibrate. HDL-mediated cholesterol efflux was determined by incubating the test HDL with labeled cells for 4 hours at 37°C. Radioactivity in the supernatants and total cell extracts were measured and expressed as the percentage of total radioactive counts removed from the cells during the efflux period.
In Vivo Reverse Cholesterol Efflux From Macrophages
Two-month-old apoE-null female mice were maintained in metabolic cages, and 100 µg/mL of D-4F or scrambled D-4F was added to their drinking water. Twelve hours later, the mice were injected intraperitoneally with 5x106 J774 cholesterol-loaded macrophages containing 1.5x106 cpm of 3H cholesterol as described by Zhang et al.10 Twenty-four hours later, the mice were killed, and lipid extracts from plasma, liver, and feces were analyzed for 3H tracer as described.10
Other Procedures
Paraoxonase activity was measured as described previously.3 Lipoprotein cholesterol concentrations were determined by use of a Cholesterol-20 kit (Sigma). For Western analyses, plasma (0.5 µL) was subjected to SDS-PAGE (4% to 20% Tris glycine from Novex) and Western-transferred (semidry onto nitrocellulose from Amersham). The blots were treated sequentially with rabbit anti-mouse apoA-I (Biodesign International K23500R), followed by horseradish peroxidase–labeled anti-rabbit IgG F(ab')2 (Jackson) and Amersham enzyme-linked chemiluminescence reagent, and exposed to film (Amersham). Two-dimensional agarose/native PAGE was performed as described previously.11 15-Hydroxyeicosatetraenoic acid (15-HETE) was measured by mass spectrometry.12 Negative staining of lipoproteins13 and determination of lipoprotein lipid hydroperoxides14 were as described previously. Statistical significance was determined by use of model I ANOVA, and significance was defined as a value of P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In Vitro Studies
The addition of 500 µg/mL of D-4F (but not scrambled D-4F) for 20 minutes to apoE-null plasma in vitro resulted in a dramatic shift of apoA-I from
migrating to pre-ß migrating particles (Figure 1). Addition of D-4F (but not scrambled D-4F) to wild-type C57BL/6J mouse plasma in vitro increased apoA-I in pre-ß migrating particles (data not shown). FPLC fractions of apoE-null mouse plasma after addition of D-4F in vitro revealed a decrease in HDL cholesterol and an increase in cholesterol-containing particles (CCPs) found in the trailing peak after the bulk HDL peak, where pre-ß HDL were found (see Figure 3A above, and data not shown). ApoE-null mouse plasma contains increased lipid peroxidation products.15 After addition of D-4F to apoE-null mouse plasma in vitro, 15-HETE was found to be concentrated in the fractions in which pre-ß HDL would be expected (data not shown).
|
|
In Vivo Studies
Twenty minutes after 500 µg of D-4F (dissolved in 200 µL of water and given by stomach tube) was administered to apoE-null mice, the plasma concentration of D-4F was 
60 pmol/mL, or 138 ng of D-4F/mL as measured by liquid chromatography multiple reaction monitoring, and 85% of the D-4F was found in HDL in the experiments shown in Figures 2
through 4. In other experiments, the highest plasma concentration observed 20 minutes after administration of 500 µg of D-4F (dissolved in 200 µL of water and given by stomach tube) to apoE-null mice was 140 pmol/mL, or 322 ng of D-4F/mL plasma. Twenty minutes after administration of 500 µg of scrambled D-4F, no peptide was detected in the plasma. As shown in Figure 2A, 20 minutes after oral D-4F, apoA-I was found in smaller particles (7 to 8 nm) in the FPLC fractions of mouse plasma in which pre-ß HDL would be expected. The formation of these small HDL-like particles was confirmed by negative staining electron microscopy (data not shown). Twenty minutes after oral D-4F, there was a marked increase in apoA-I with pre-ß mobility (Figure 2B). A similar increase in apoA-I with pre-ß mobility was seen 20 minutes after oral D-4F in wild-type C57BL/6J mice (data not shown). Twenty minutes after oral D-4F, the FPLC fractions in which pre-ß HDL would be expected also contained increased cholesterol and paraoxonase activity (Figure 3A). Twenty minutes after oral D-4F, HDL and the FPLC fractions in which pre-ß HDL would be expected were converted from proinflammatory to antiinflammatory (Figure 3B). Paralleling the improvement in HDL inflammatory/antiinflammatory properties, 20 minutes after oral D-4F (but not scrambled D-4F), there was also a significant improvement in the ability of apoE-null HDL to mediate cholesterol efflux from human monocyte macrophages (Figure 4). The data shown in Figures 2, 3, and 4 represent experiments with female apoE-null mice. Similar results were found in male apoE-null mice, and no differences were observed when scrambled D-4F or water alone was used as the control (data not shown).
|
|
Oral D-4F significantly stimulated reverse cholesterol transport from intraperitoneally injected macrophages into plasma, liver, and feces in vivo (Figure 5). ApoE-null lipoproteins contain elevated levels of oxidized lipids.14 If oral D-4F causes the formation of pre-ß HDL enriched in apoA-I and paraoxonase, one might expect oral D-4F to decrease lipoprotein lipid hydroperoxides. This was indeed the case for oral D-4F (but not for scrambled D-4F) for VLDL/IDL (Figure 6A), LDL (Figure 6B), and HDL (Figure 6C). After oral D-4F, in the female apo E-null mice shown in Figure 6C, there were no detectable lipid hydroperoxides in HDL. In contrast, as shown in Figure 6D, there was a significant increase in lipid hydroperoxides 20 minutes after oral D-4F (but not after scrambled D-4F) in the FPLC fractions in which pre-ß HDL would be expected. Total plasma lipid hydroperoxides were decreased after oral D-4F (data not shown). In male apoE-null and in wild-type C57BL/6J mice, there was a very significant decrease in HDL lipid hydroperoxides 20 minutes after oral D-4F, but they were detectable (data not shown). In male apoE-null and in wild-type C57BL/6J mice, there was also a significant increase in pre-ß HDL lipid hydroperoxides (data not shown). As expected, FPLC fractions coming off the column after pre-ß HDL, which do not contain lipoproteins, did not contain lipid hydroperoxides (Figure 6E). There was also an increase in paraoxonase activity after oral D-4F in the HDL and pre-ß HDL FPLC fractions, and the total plasma paraoxonase activity was increased (data not shown). Moreover, in the coculture assay, the pre-ß HDL fractions were anti-inflammatory, despite the increased lipoprotein lipid hydroperoxides (LOOH) content (data not shown).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In vitro, D-4F caused a dramatic redistribution of apoA-I from
migrating to ß migrating particles in apoE-null mouse plasma (Figure 1), suggesting that D-4F is acting directly on HDL or some plasma component that in turn remodels HDL. In vivo, in apoE-null mice, despite the small amount of D-4F absorbed 20 minutes after an oral dose, D-4F rapidly caused the formation of CCPs (Figure 3A) with pre-ß mobility (Figure 2B) that were enriched in apoA-I (Figure 2A) and paraoxonase activity (Figure 3A). Twenty minutes after oral D-4F, proinflammatory HDL became antiinflammatory (Figure 3B), and the ability of the HDL to mediate cholesterol efflux from macrophages in vitro was enhanced (Figure 4). Oral D-4F also stimulated reverse cholesterol transport from macrophages in vivo in apoE-null mice (Figure 5). After oral D-4F (but not scrambled D-4F), LOOH decreased in all lipoprotein fractions except those in which pre-ß HDL would be expected (Figure 6). The fractions in which pre-ß HDL would be expected were antiinflammatory 20 minutes after oral D-4F (Figure 3B). After feeding D-4F overnight, LOOH was increased in the pre-ß HDL FPLC fractions (Figure 6D). At this time, paraoxonase activity was also increased in the pre-ß HDL FPLC fractions, and these fractions were anti-inflammatory in the coculture assay (data not shown). Thus, the increase in paraoxonase activity must have more than compensated for the increased LOOH in terms of reducing the proinflammatory-oxidized phospholipids in these fractions. The failure to detect scrambled D-4F (which does not bind lipids) in the plasma 20 minutes after oral administration may indicate that the lipid-binding properties of D-4F are critical to its absorption. Alternatively, the scrambled D-4F may have been absorbed, but because of its inability to bind lipids, it may have been rapidly cleared from plasma, as is the case for lipid-poor apoA-I in Tangiers disease. Reverse cholesterol transport is considered to be important in preventing the buildup of lipids that predisposes to atherosclerosis.16 Reddy and colleagues17 demonstrated in vitro that an increase in cellular cholesterol levels caused human artery wall cells to increase the formation of LDL-derived oxidized phospholipids that are thought to initiate the inflammatory response in atherosclerosis.18 Pre-ß HDL is generally considered to be the most active HDL fraction in promoting reverse cholesterol transport, and the cycling of cholesterol through pre-ß HDL is generally considered to be protective against atherosclerosis.19 The data presented in this article suggest that oral D-4F provides a novel method for stimulating the formation pre-ß HDL and stimulating reverse cholesterol transport from macrophages. These properties of oral D-4F may account for its remarkable ability to reduce lesions in mouse models of atherosclerosis.2 The ability of oral D-4F to cause pre-ß HDL formation in wild-type C57BL/6J mice on a chow diet, to decrease LOOH in HDL, and to increase LOOH in pre-ß HDL in these mice (data not shown), together with the ability of oral D-4F to render HDL antiinflammatory and dramatically reduce atherosclerosis in LDL receptor-null mice,2 suggests that these properties are not dependent on the absence of apoE.
|
Acknowledgments |
|---|
This work was supported in part by US Public Health Services grants HL-30568 and HL-34343 and the Laubisch, Castera, and M.K. Grey Funds at UCLA. We thank Dr Kym Faull and Dr Julian Whitelegge for their expert valuable assistance with mass spectrometry analyses.
|
Footnotes |
|---|
M.N., S.H., S.T.R., G.M.A., and A.M.F. are principals in Bruin Pharma.
An online Data Supplement is available at http://www.circulationaha.org.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001; 42: 1096–1104.
2. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105: 290–292.
3. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002; 106: 1127–1132.
4. Ou Z, Ou J, Ackerman AW, et al. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein–treated endothelial cells. Circulation. 2003; 107: 1520–1524.
5. Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003; 107: 2337–2341.
6. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001; 42: 545–552.
7. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001; 42: 1308–1317.
8. Whitelegge JP, Le Coutre J, Lee JC, et al. Toward the bilayer proteome, electrospray ionization-mass spectrometry of large, intact transmembrane proteins. Proc Natl Acad Sci U S A. 1999;96:10695–10698.
9. Remaley AT, Thomas F, Stonik JA, et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res. 2003; 44: 828–836.
10. Zhang YZ, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003; 108: 661–663.
11. Jiang X-C, Francone OL, Bruce C, et al. Increased pre-ß-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996; 98: 2373–2380.[Medline] [Order article via Infotrieve]
12. Mallat Z, Nakamura T, Ohan J, et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest. 1999; 103: 421–427.[Medline] [Order article via Infotrieve]
13. Frank JS, Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J Lipid Res. 1989; 30: 967–978.[Abstract]
14. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001; 103: 2283–2288.
15. Cyrus T, Pratico D, Zhao L, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E–deficient mice. Circulation. 2001; 103: 2277–2282.
16. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E–deficient mice: potential implications for acute plaque stabilization. Circulation. 2001; 103: 3047–3050.
17. Reddy ST, Hama S, Ng C, et al. ATP binding cassette transporter 1 participates in LDL oxidation by artery wall cells. Arterioscler Thromb Vasc Biol. 2002; 22: 1877–1883.
18. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001; 21: 481–488.
19. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochem Biophys Acta. 2001; 1533: 175–189.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman HDL as a Biomarker, Potential Therapeutic Target, and Therapy Diabetes, December 1, 2009; 58(12): 2711 - 2717. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zerrad-Saadi, P. Therond, S. Chantepie, M. Couturier, K.-A. Rye, M. J. Chapman, and A. Kontush HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Wool, T. Vaisar, C. A. Reardon, and G. S. Getz An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide J. Lipid Res., September 1, 2009; 50(9): 1889 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, P. Ruchala, A. J. Waring, R. I. Lehrer, S. Hama, G. Hough, M. N. Palgunachari, G. M. Anantharamaiah, and A. M. Fogelman A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids J. Lipid Res., August 1, 2009; 50(8): 1538 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, G. Datta, Y. Zhang, A. P. Miller, P. Mochon, Y.-F. Chen, J. Chatham, G. M. Anantharamaiah, and C. R. White Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H866 - H873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Watanabe, V. Grijalva, S. Hama, K. Barbour, F. G. Berger, M. Navab, A. M. Fogelman, and S. T. Reddy Hemoglobin and Its Scavenger Protein Haptoglobin Associate with ApoA-1-containing Particles and Influence the Inflammatory Properties and Function of High Density Lipoprotein J. Biol. Chem., July 3, 2009; 284(27): 18292 - 18301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Peterson, D. H. Kim, M. Li, V. Positano, L. Vanella, L. F. Rodella, F. Piccolomini, N. Puri, A. Gastaldelli, C. Kusmic, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice J. Lipid Res., July 1, 2009; 50(7): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, J. Sanz, and V. Fuster Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2315 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman The role of dysfunctional HDL in atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S145 - S149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Greaves and S. Gordon The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges J. Lipid Res., April 1, 2009; 50(Supplement): S282 - S286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Mishra, M. N. Palgunachari, N. R. Krishna, J. Glushka, J. P. Segrest, and G. M. Anantharamaiah Effect of Leucine to Phenylalanine Substitution on the Nonpolar Face of a Class A Amphipathic Helical Peptide on Its Interaction with Lipid: HIGH RESOLUTION SOLUTION NMR STUDIES OF 4F-DIMYRISTOYLPHOSPHATIDYLCHOLINE DISCOIDAL COMPLEX J. Biol. Chem., December 5, 2008; 283(49): 34393 - 34402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Scanu and C. Edelstein HDL: bridging past and present with a look at the future FASEB J, December 1, 2008; 22(12): 4044 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Postgrad. Med. J., November 1, 2008; 84(997): 590 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. DeLeve, X. Wang, G. C. Kanel, R. D. Atkinson, and R. S. McCuskey Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Nonalcoholic Steatohepatitis Am. J. Pathol., October 1, 2008; 173(4): 993 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Choi, A. Chae, E. Miller, M. Messig, F. Ntanios, A. N. DeMaria, S. E. Nissen, J. L. Witztum, and S. Tsimikas Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume Observations From the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) Study. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Wool, C. A. Reardon, and G. S. Getz Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties J. Lipid Res., June 1, 2008; 49(6): 1268 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J. Lipid Res., June 1, 2008; 49(6): 1344 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Troutt, W. E. Alborn, M. K. Mosior, J. Dai, A. T. Murphy, T. P. Beyer, Y. Zhang, G. Cao, and R. J. Konrad An apolipoprotein A-I mimetic dose-dependently increases the formation of pre{beta}1 HDL in human plasma J. Lipid Res., March 1, 2008; 49(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Van Lenten, A. C. Wagner, M. Navab, G. M. Anantharamaiah, S. Hama, S. T. Reddy, and A. M. Fogelman Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits J. Lipid Res., November 1, 2007; 48(11): 2344 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Weihrauch, H. Xu, Y. Shi, J. Wang, J. Brien, D. W. Jones, S. Kaul, R. A. Komorowski, M. E. Csuka, K. T. Oldham, et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1432 - H1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Watanabe, K. J. Chou, J. C. Liao, Y. Miao, H.-H. Meng, H. Ge, V. Grijalva, S. Hama, K. Kozak, G. Buga, et al. Differential Association of Hemoglobin with Proinflammatory High Density Lipoproteins in Atherogenic/Hyperlipidemic Mice: A NOVEL BIOMARKER OF ATHEROSCLEROSIS J. Biol. Chem., August 10, 2007; 282(32): 23698 - 23707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Peterson, D. Husney, A. L. Kruger, R. Olszanecki, F. Ricci, L. F. Rodella, A. Stacchiotti, R. Rezzani, J. A. McClung, W. S. Aronow, et al. Long-Term Treatment with the Apolipoprotein A1 Mimetic Peptide Increases Antioxidants and Vascular Repair in Type I Diabetic Rats J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Ng, N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy Adenovirus-Mediated Expression of Human Paraoxonase 3 Protects Against the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, M. Aikawa, F. J. Miller Jr, E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Buga, J. S. Frank, G. A. Mottino, M. Hendizadeh, A. Hakhamian, J. H. Tillisch, S. T. Reddy, M. Navab, G. M. Anantharamaiah, L. J. Ignarro, et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet J. Lipid Res., October 1, 2006; 47(10): 2148 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, X. Wang, C. Vales, F. Y. Lee, H. Lee, A. J. Lusis, and P. A. Edwards FXR Deficiency Causes Reduced Atherosclerosis in Ldlr-/- Mice Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2316 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow High-Density Lipoprotein Function: Recent Advances J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1792 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al. Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice Circ. Res., September 16, 2005; 97(6): 524 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gupta, L. Dai, G. Datta, D. W. Garber, H. Grenett, Y. Li, V. Mishra, M. N. Palgunachari, S. Handattu, S. H. Gianturco, et al. Inhibition of Lipopolysaccharide-Induced Inflammatory Responses by an Apolipoprotein AI Mimetic Peptide Circ. Res., August 5, 2005; 97(3): 236 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kruger, S. Peterson, S. Turkseven, P. M. Kaminski, F. F. Zhang, S. Quan, M. S. Wolin, and N. G. Abraham D-4F Induces Heme Oxygenase-1 and Extracellular Superoxide Dismutase, Decreases Endothelial Cell Sloughing, and Improves Vascular Reactivity in Rat Model of Diabetes Circulation, June 14, 2005; 111(23): 3126 - 3134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gupta, C. R. White, S. Handattu, D. W. Garber, G. Datta, M. Chaddha, L. Dai, S. H. Gianturco, W. A. Bradley, and G.M. Anantharamaiah Apolipoprotein E Mimetic Peptide Dramatically Lowers Plasma Cholesterol and Restores Endothelial Function in Watanabe Heritable Hyperlipidemic Rabbits Circulation, June 14, 2005; 111(23): 3112 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schneider, J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins J. Lipid Res., April 1, 2005; 46(4): 769 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Epand, R. F. Epand, B. G. Sayer, G. Datta, M. Chaddha, and G. M. Anantharamaiah Two Homologous Apolipoprotein AI Mimetic Peptides: RELATIONSHIP BETWEEN MEMBRANE INTERACTIONS AND BIOLOGICAL ACTIVITY J. Biol. Chem., December 3, 2004; 279(49): 51404 - 51414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. L. Witztum, E. R. Miller, W. J. Sasiela, M. Szarek, A. G. Olsson, G. G. Schwartz, and for the Myocardial Ischemia Reduction with Aggress High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial Circulation, September 14, 2004; 110(11): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||